(Q51565479)

7 April 2018

title

Rebound hypersecretion after omeprazole and its relation to on-treatment acid suppression and Helicobacter pylori status. (English)

1 reference

7 April 2018

Helicobacter pylori infectious disease

0 references

1 reference

1 reference

D Gillen

1

1 reference

7 April 2018

A A Wirz

series ordinal

2

1 reference

7 April 2018

J E Ardill

series ordinal

3

1 reference

7 April 2018

K E McColl

series ordinal

4

1 reference

7 April 2018

language of work or name

English

0 references

publication date

1 February 1999

1 reference

7 April 2018

published in

Gastroenterology

1 reference

7 April 2018

volume

116

1 reference

7 April 2018

issue

2

1 reference

7 April 2018

page(s)

239-247

1 reference

7 April 2018

1976 and all that!--20 years of antisecretory therapy

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970118-6

Effects of single and repeated doses of omeprazole on gastric acid and pepsin secretion in man

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970118-6

Omeprazole in duodenal ulceration: acid inhibition, symptom relief, endoscopic healing, and recurrence. Cooperative study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970118-6

The relationship between suppression of acidity and gastric ulcer healing rates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970118-6

Long-term maintenance treatment of reflux esophagitis with omeprazole. Prospective study in patients with H2-blocker-resistant esophagitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970118-6

Nocturnal intragastric acidity during and after a period of dosing with either ranitidine or omeprazole.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970118-6

Marked increase in gastric acid secretory capacity after omeprazole treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970118-6

Effect of Helicobacter pylori status on intragastric pH during treatment with omeprazole

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970118-6

Effect of curing Helicobacter pylori infection on intragastric pH during treatment with omeprazole

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970118-6

Helicobacter pylori augments the pH-increasing effect of omeprazole in patients with duodenal ulcer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970118-6

Comparison of helisal rapid blood test and 14C-urea breath test in determining Helicobacter pylori status and predicting ulcer disease in dyspeptic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970118-6

Positioning of Subject and of Nasogastric Tube during a Gastric Secretion Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970118-6

Helicobacter pylori related hypergastrinaemia is the result of a selective increase in gastrin 17

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970118-6

The acid response to gastrin distinguishes duodenal ulcer patients from Helicobacter pylori-infected healthy subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970118-6

Optimal dose of oral omeprazole for maximal 24 hour decrease of intragastric acidity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970118-6

Gastrin produces an immediate and dose-dependent histamine release preceding acid secretion in the totally isolated, vascularly perfused rat stomach

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970118-6

Studies of Isolated Parietal and Enterochromaffin-Like Cells from the Rat

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970118-6

Histamine secretion from rat enterochromaffinlike cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970118-6

Neural and paracrine regulation of gastrin and gastric acid secretion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970118-6

Definition and antagonism of histamine H 2 -receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970118-6

Effect of short- and long-term feeding of omeprazole on rat gastric endocrine cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970118-6

Lansoprazole and omeprazole have similar effects on plasma gastrin levels, enterochromaffin-like cells, gastrin cells and somatostatin cells in the rat stomach

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970118-6

Long-term treatment with omeprazole for refractory reflux esophagitis: efficacy and safety.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970118-6

Gastric mucosa during treatment with lansoprazole: Helicobacter pylori is a risk factor for argyrophil cell hyperplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970118-6

Plasma gastrin and gastric enterochromaffinlike cell activation and proliferation. Studies with omeprazole and ranitidine in intact and antrectomized rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970118-6

Effect of gastrin receptor blockade on endocrine cells in rats during achlorhydria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970118-6

Differential control of somatostatin messenger RNA in rat gastric corpus and antrum. Role of acid, food, and capsaicin-sensitive afferent neurons

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970118-6

Changes in the intragastric distribution of Helicobacter pylori during treatment with omeprazole

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970118-6

Improved fold width and increased acid secretion after eradication of the organism in Helicobacter pylori associated enlarged fold gastritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970118-6

Effects of aging and gastritis on gastric acid and pepsin secretion in humans: a prospective study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970118-6

Helicobacter pylori infection and chronic gastric acid hyposecretion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970118-6

Effect of a Campylobacter pylori protein on acid secretion by parietal cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970118-6

Interaction of Helicobacter pylori and its fatty acids with parietal cells and gastric H+/K(+)-ATPase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970118-6

Interleukin-1 is cytoprotective, antisecretory, stimulates PGE2 synthesis by the stomach, and retards gastric emptying

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970118-6

Functional impairment of rat enterochromaffin-like cells by interleukin 1 beta

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970118-6

Eradicating Helicobacter pylori reduces hypergastrinaemia during long-term omeprazole treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970118-6

Augmented postprandial gastric acid secretion due to exposure to ranitidine in healthy subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970118-6

Rebound nocturnal hypersecretion after four weeks treatment with an H2 receptor antagonist

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970118-6

Changes in nocturnal and peak acid outputs after duodenal ulcer healing with sucralfate or ranitidine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970118-6

Rebound intragastric hyperacidity after abrupt withdrawal of histamine H2 receptor blockade

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970118-6

Helicobacter pylori infection and abnormalities of acid secretion in patients with duodenal ulcer disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970118-6

Multivariate analysis of pathophysiological factors in reflux oesophagitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970118-6

Role of gastric acid suppression in the treatment of gastro-oesophageal reflux disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970118-6

Appropriate acid suppression for the management of gastro-oesophageal reflux disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970118-6

Rolling review: gastro-oesophageal reflux disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970118-6

Review article: the pharmacological inhibition of gastric acid secretion--tolerance and rebound

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970118-6

Long-term efficacy and safety of omeprazole in patients with Zollinger-Ellison syndrome: a prospective study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970118-6

inferred from DOI database lookup

7 January 2021

based on heuristic

Total 24-hour gastric acid secretion in patients with duodenal ulcer. Comparison with normal subjects and effects of cimetidine and parietal cell vagotomy

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970118-6

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0016-5085(99)70118-6

1 reference

7 April 2018

PubMed ID

9922302

1 reference

7 April 2018